HIGHLY ATTENUATED SIV VIF DNA VACCINES

高度减毒 SIV VIF DNA 疫苗

• 批准号: 7349657
• 负责人: Ellen Elizabeth Sparger
• 金额: $ 11.75万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-01 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7349657
• 关键词: HIGHLY; ATTENUATED; SIV; VIF; DNA

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective: Studies in nonhuman primates with simian immunodeficiency virus (SIV) have demonstrated that live-attenuated viruses are highly effective; however, such vaccines maintain a low level of pathogenicity. The objective of this study was to test the immunogenicity of a SIVdeltavif proviral DNA vaccine administered by the IM and ID routes in rhesus macaques and to test for vaccine efficacy by challenge with pathogenic SIVmac251.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。目的：在非人类免疫缺陷病毒（SIV）的非人类灵长类动物中的研究表明，活衰减的病毒非常有效。但是，这种疫苗的致病水平较低。这项研究的目的是测试由恒河猕猴中IM和ID途径施用的Sivdeltavif前病毒DNA疫苗的免疫原性，并通过致病性SIVMAC251挑战来测试疫苗功效。